nodes	percent_of_prediction	percent_of_DWPC	metapath
Conivaptan—Atorvastatin—AHR—liver cancer	0.0293	1	CrCbGaD
Conivaptan—Electrocardiogram ST segment depression—Epirubicin—liver cancer	0.0244	0.0485	CcSEcCtD
Conivaptan—Electrocardiogram ST segment depression—Doxorubicin—liver cancer	0.0226	0.0449	CcSEcCtD
Conivaptan—Cardiac failure—Sorafenib—liver cancer	0.0112	0.0222	CcSEcCtD
Conivaptan—Hyponatraemia—Sorafenib—liver cancer	0.0109	0.0217	CcSEcCtD
Conivaptan—Dehydration—Sorafenib—liver cancer	0.0101	0.0201	CcSEcCtD
Conivaptan—Hypokalaemia—Sorafenib—liver cancer	0.00992	0.0197	CcSEcCtD
Conivaptan—Hypomagnesaemia—Epirubicin—liver cancer	0.00874	0.0173	CcSEcCtD
Conivaptan—Oral candidiasis—Epirubicin—liver cancer	0.00874	0.0173	CcSEcCtD
Conivaptan—Pneumonia—Sorafenib—liver cancer	0.00845	0.0168	CcSEcCtD
Conivaptan—Infestation—Sorafenib—liver cancer	0.0084	0.0167	CcSEcCtD
Conivaptan—Infestation NOS—Sorafenib—liver cancer	0.0084	0.0167	CcSEcCtD
Conivaptan—Oral candidiasis—Doxorubicin—liver cancer	0.00808	0.016	CcSEcCtD
Conivaptan—Hypomagnesaemia—Doxorubicin—liver cancer	0.00808	0.016	CcSEcCtD
Conivaptan—Urinary tract disorder—Sorafenib—liver cancer	0.00745	0.0148	CcSEcCtD
Conivaptan—Urethral disorder—Sorafenib—liver cancer	0.00739	0.0147	CcSEcCtD
Conivaptan—Cardiac disorder—Sorafenib—liver cancer	0.007	0.0139	CcSEcCtD
Conivaptan—Angiopathy—Sorafenib—liver cancer	0.00684	0.0136	CcSEcCtD
Conivaptan—Mediastinal disorder—Sorafenib—liver cancer	0.0068	0.0135	CcSEcCtD
Conivaptan—Mental disorder—Sorafenib—liver cancer	0.00661	0.0131	CcSEcCtD
Conivaptan—Erythema—Sorafenib—liver cancer	0.00656	0.013	CcSEcCtD
Conivaptan—Malnutrition—Sorafenib—liver cancer	0.00656	0.013	CcSEcCtD
Conivaptan—Anaemia—Sorafenib—liver cancer	0.00607	0.012	CcSEcCtD
Conivaptan—Hypertension—Sorafenib—liver cancer	0.00567	0.0113	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00555	0.011	CcSEcCtD
Conivaptan—Dry mouth—Sorafenib—liver cancer	0.00547	0.0109	CcSEcCtD
Conivaptan—Infection—Sorafenib—liver cancer	0.00532	0.0106	CcSEcCtD
Conivaptan—Candida infection—Epirubicin—liver cancer	0.0053	0.0105	CcSEcCtD
Conivaptan—Nervous system disorder—Sorafenib—liver cancer	0.00525	0.0104	CcSEcCtD
Conivaptan—Skin disorder—Sorafenib—liver cancer	0.0052	0.0103	CcSEcCtD
Conivaptan—Candida infection—Doxorubicin—liver cancer	0.0049	0.00973	CcSEcCtD
Conivaptan—Sepsis—Epirubicin—liver cancer	0.00482	0.00956	CcSEcCtD
Conivaptan—Phlebitis—Epirubicin—liver cancer	0.00468	0.00928	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Sorafenib—liver cancer	0.00463	0.00918	CcSEcCtD
Conivaptan—Pain—Sorafenib—liver cancer	0.00458	0.0091	CcSEcCtD
Conivaptan—Constipation—Sorafenib—liver cancer	0.00458	0.0091	CcSEcCtD
Conivaptan—Sepsis—Doxorubicin—liver cancer	0.00446	0.00885	CcSEcCtD
Conivaptan—Phlebitis—Doxorubicin—liver cancer	0.00433	0.00859	CcSEcCtD
Conivaptan—Body temperature increased—Sorafenib—liver cancer	0.00424	0.00841	CcSEcCtD
Conivaptan—Cardiac failure—Epirubicin—liver cancer	0.00413	0.0082	CcSEcCtD
Conivaptan—Hypoglycaemia—Epirubicin—liver cancer	0.00413	0.0082	CcSEcCtD
Conivaptan—Hyponatraemia—Epirubicin—liver cancer	0.00404	0.00803	CcSEcCtD
Conivaptan—Hypoglycaemia—Doxorubicin—liver cancer	0.00382	0.00758	CcSEcCtD
Conivaptan—Cardiac failure—Doxorubicin—liver cancer	0.00382	0.00758	CcSEcCtD
Conivaptan—Pruritus—Sorafenib—liver cancer	0.00379	0.00753	CcSEcCtD
Conivaptan—Dehydration—Epirubicin—liver cancer	0.00375	0.00744	CcSEcCtD
Conivaptan—Hyponatraemia—Doxorubicin—liver cancer	0.00374	0.00743	CcSEcCtD
Conivaptan—Orthostatic hypotension—Epirubicin—liver cancer	0.00368	0.0073	CcSEcCtD
Conivaptan—Hypokalaemia—Epirubicin—liver cancer	0.00367	0.00728	CcSEcCtD
Conivaptan—Diarrhoea—Sorafenib—liver cancer	0.00367	0.00728	CcSEcCtD
Conivaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.00349	0.00748	CbGpPWpGaD
Conivaptan—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—liver cancer	0.00348	0.00745	CbGpPWpGaD
Conivaptan—Dehydration—Doxorubicin—liver cancer	0.00347	0.00688	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.00344	0.00736	CbGpPWpGaD
Conivaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.00344	0.00736	CbGpPWpGaD
Conivaptan—Vomiting—Sorafenib—liver cancer	0.00341	0.00676	CcSEcCtD
Conivaptan—Orthostatic hypotension—Doxorubicin—liver cancer	0.0034	0.00676	CcSEcCtD
Conivaptan—Hypokalaemia—Doxorubicin—liver cancer	0.00339	0.00673	CcSEcCtD
Conivaptan—Headache—Sorafenib—liver cancer	0.00336	0.00666	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.00328	0.00702	CbGpPWpGaD
Conivaptan—Pollakiuria—Epirubicin—liver cancer	0.00322	0.00639	CcSEcCtD
Conivaptan—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	0.00321	0.00688	CbGpPWpGaD
Conivaptan—Nausea—Sorafenib—liver cancer	0.00318	0.00632	CcSEcCtD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCE—liver cancer	0.00316	0.00678	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—ANXA2—liver cancer	0.00314	0.00673	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—ATP7B—liver cancer	0.00314	0.00673	CbGpPWpGaD
Conivaptan—Hyperglycaemia—Epirubicin—liver cancer	0.00314	0.00624	CcSEcCtD
Conivaptan—Pneumonia—Epirubicin—liver cancer	0.00312	0.0062	CcSEcCtD
Conivaptan—Infestation—Epirubicin—liver cancer	0.0031	0.00616	CcSEcCtD
Conivaptan—Infestation NOS—Epirubicin—liver cancer	0.0031	0.00616	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—CCR4—liver cancer	0.0031	0.00664	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CCR4—liver cancer	0.00308	0.00659	CbGpPWpGaD
Conivaptan—Urinary tract infection—Epirubicin—liver cancer	0.00302	0.00599	CcSEcCtD
Conivaptan—Pollakiuria—Doxorubicin—liver cancer	0.00298	0.00591	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—NR1H4—liver cancer	0.00297	0.00636	CbGpPWpGaD
Conivaptan—Haematuria—Epirubicin—liver cancer	0.00296	0.00588	CcSEcCtD
Conivaptan—CYP3A4—Xenobiotics—CYP2E1—liver cancer	0.00291	0.00623	CbGpPWpGaD
Conivaptan—Hyperglycaemia—Doxorubicin—liver cancer	0.00291	0.00577	CcSEcCtD
Conivaptan—Pneumonia—Doxorubicin—liver cancer	0.00289	0.00574	CcSEcCtD
Conivaptan—Infestation—Doxorubicin—liver cancer	0.00287	0.0057	CcSEcCtD
Conivaptan—Infestation NOS—Doxorubicin—liver cancer	0.00287	0.0057	CcSEcCtD
Conivaptan—CYP3A4—Tamoxifen metabolism—CYP2E1—liver cancer	0.0028	0.00599	CbGpPWpGaD
Conivaptan—Urinary tract infection—Doxorubicin—liver cancer	0.00279	0.00554	CcSEcCtD
Conivaptan—CYP3A4—Aflatoxin activation and detoxification—GGT1—liver cancer	0.00278	0.00596	CbGpPWpGaD
Conivaptan—Urinary tract disorder—Epirubicin—liver cancer	0.00275	0.00546	CcSEcCtD
Conivaptan—Oedema peripheral—Epirubicin—liver cancer	0.00275	0.00545	CcSEcCtD
Conivaptan—Haematuria—Doxorubicin—liver cancer	0.00274	0.00544	CcSEcCtD
Conivaptan—Urethral disorder—Epirubicin—liver cancer	0.00273	0.00542	CcSEcCtD
Conivaptan—Cardiac disorder—Epirubicin—liver cancer	0.00259	0.00513	CcSEcCtD
Conivaptan—Urinary tract disorder—Doxorubicin—liver cancer	0.00255	0.00506	CcSEcCtD
Conivaptan—Oedema peripheral—Doxorubicin—liver cancer	0.00254	0.00504	CcSEcCtD
Conivaptan—Angiopathy—Epirubicin—liver cancer	0.00253	0.00502	CcSEcCtD
Conivaptan—Urethral disorder—Doxorubicin—liver cancer	0.00253	0.00502	CcSEcCtD
Conivaptan—Mediastinal disorder—Epirubicin—liver cancer	0.00251	0.00499	CcSEcCtD
Conivaptan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—liver cancer	0.0025	0.00535	CbGpPWpGaD
Conivaptan—AVPR1A—G alpha (q) signalling events—F2—liver cancer	0.00246	0.00526	CbGpPWpGaD
Conivaptan—Mental disorder—Epirubicin—liver cancer	0.00244	0.00485	CcSEcCtD
Conivaptan—Erythema—Epirubicin—liver cancer	0.00243	0.00482	CcSEcCtD
Conivaptan—Malnutrition—Epirubicin—liver cancer	0.00243	0.00482	CcSEcCtD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—F2—liver cancer	0.00243	0.00519	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—F2—liver cancer	0.00241	0.00516	CbGpPWpGaD
Conivaptan—CYP3A4—Estrogen metabolism—GSTM1—liver cancer	0.0024	0.00514	CbGpPWpGaD
Conivaptan—Cardiac disorder—Doxorubicin—liver cancer	0.00239	0.00475	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—CHN2—liver cancer	0.00236	0.00505	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CHN2—liver cancer	0.00234	0.00502	CbGpPWpGaD
Conivaptan—Angiopathy—Doxorubicin—liver cancer	0.00234	0.00464	CcSEcCtD
Conivaptan—Mediastinal disorder—Doxorubicin—liver cancer	0.00232	0.00461	CcSEcCtD
Conivaptan—CYP3A4—Estrogen metabolism—CYP1A1—liver cancer	0.00227	0.00487	CbGpPWpGaD
Conivaptan—Mental disorder—Doxorubicin—liver cancer	0.00226	0.00449	CcSEcCtD
Conivaptan—Erythema—Doxorubicin—liver cancer	0.00224	0.00446	CcSEcCtD
Conivaptan—Malnutrition—Doxorubicin—liver cancer	0.00224	0.00446	CcSEcCtD
Conivaptan—Anaemia—Epirubicin—liver cancer	0.00224	0.00445	CcSEcCtD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.00222	0.00475	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—F2—liver cancer	0.0022	0.0047	CbGpPWpGaD
Conivaptan—CYP3A4—Irinotecan Pathway—APC—liver cancer	0.00218	0.00466	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IFT88—liver cancer	0.00216	0.00462	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IFT88—liver cancer	0.00214	0.00459	CbGpPWpGaD
Conivaptan—Hypertension—Epirubicin—liver cancer	0.00209	0.00416	CcSEcCtD
Conivaptan—CYP3A4—Xenobiotics—CYP1A1—liver cancer	0.00209	0.00448	CbGpPWpGaD
Conivaptan—Anaemia—Doxorubicin—liver cancer	0.00207	0.00412	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00205	0.00407	CcSEcCtD
Conivaptan—Dry mouth—Epirubicin—liver cancer	0.00202	0.00401	CcSEcCtD
Conivaptan—CYP3A4—Tamoxifen metabolism—CYP1A1—liver cancer	0.00201	0.00431	CbGpPWpGaD
Conivaptan—Confusional state—Epirubicin—liver cancer	0.002	0.00396	CcSEcCtD
Conivaptan—Infection—Epirubicin—liver cancer	0.00197	0.00391	CcSEcCtD
Conivaptan—Nervous system disorder—Epirubicin—liver cancer	0.00194	0.00385	CcSEcCtD
Conivaptan—Hypertension—Doxorubicin—liver cancer	0.00194	0.00385	CcSEcCtD
Conivaptan—Skin disorder—Epirubicin—liver cancer	0.00192	0.00382	CcSEcCtD
Conivaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.0019	0.00408	CbGpPWpGaD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.0019	0.00377	CcSEcCtD
Conivaptan—Dry mouth—Doxorubicin—liver cancer	0.00187	0.00371	CcSEcCtD
Conivaptan—Hypotension—Epirubicin—liver cancer	0.00185	0.00367	CcSEcCtD
Conivaptan—Confusional state—Doxorubicin—liver cancer	0.00185	0.00367	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—TRIO—liver cancer	0.00183	0.00391	CbGpPWpGaD
Conivaptan—Infection—Doxorubicin—liver cancer	0.00182	0.00361	CcSEcCtD
Conivaptan—AVPR2—GPCR downstream signaling—TRIO—liver cancer	0.00181	0.00388	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.0018	0.00385	CbGpPWpGaD
Conivaptan—Nervous system disorder—Doxorubicin—liver cancer	0.0018	0.00357	CcSEcCtD
Conivaptan—Insomnia—Epirubicin—liver cancer	0.00179	0.00356	CcSEcCtD
Conivaptan—Skin disorder—Doxorubicin—liver cancer	0.00178	0.00353	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—CCR4—liver cancer	0.00175	0.00375	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—CCR4—liver cancer	0.00174	0.00372	CbGpPWpGaD
Conivaptan—Hypotension—Doxorubicin—liver cancer	0.00171	0.0034	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Epirubicin—liver cancer	0.00171	0.00339	CcSEcCtD
Conivaptan—Pain—Epirubicin—liver cancer	0.00169	0.00336	CcSEcCtD
Conivaptan—Constipation—Epirubicin—liver cancer	0.00169	0.00336	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—TRIO—liver cancer	0.00166	0.00355	CbGpPWpGaD
Conivaptan—Insomnia—Doxorubicin—liver cancer	0.00166	0.00329	CcSEcCtD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—liver cancer	0.00165	0.00353	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—TRIO—liver cancer	0.00165	0.00353	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—UGDH—liver cancer	0.00164	0.0035	CbGpPWpGaD
Conivaptan—Feeling abnormal—Epirubicin—liver cancer	0.00163	0.00324	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.00163	0.00348	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.00162	0.00346	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—CCR4—liver cancer	0.00159	0.00341	CbGpPWpGaD
Conivaptan—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00158	0.00314	CcSEcCtD
Conivaptan—AVPR2—Signaling by GPCR—CCR4—liver cancer	0.00158	0.00338	CbGpPWpGaD
Conivaptan—Pain—Doxorubicin—liver cancer	0.00157	0.00311	CcSEcCtD
Conivaptan—Constipation—Doxorubicin—liver cancer	0.00157	0.00311	CcSEcCtD
Conivaptan—Body temperature increased—Epirubicin—liver cancer	0.00157	0.00311	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—CYCS—liver cancer	0.00151	0.00324	CbGpPWpGaD
Conivaptan—Feeling abnormal—Doxorubicin—liver cancer	0.00151	0.003	CcSEcCtD
Conivaptan—CYP3A4—Tryptophan metabolism—CYP2E1—liver cancer	0.00149	0.0032	CbGpPWpGaD
Conivaptan—Body temperature increased—Doxorubicin—liver cancer	0.00145	0.00288	CcSEcCtD
Conivaptan—Pruritus—Epirubicin—liver cancer	0.0014	0.00278	CcSEcCtD
Conivaptan—Diarrhoea—Epirubicin—liver cancer	0.00135	0.00269	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—SHC3—liver cancer	0.00132	0.00283	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—HMOX1—liver cancer	0.00132	0.00282	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—SHC3—liver cancer	0.00131	0.00281	CbGpPWpGaD
Conivaptan—Pruritus—Doxorubicin—liver cancer	0.0013	0.00257	CcSEcCtD
Conivaptan—Vomiting—Epirubicin—liver cancer	0.00126	0.0025	CcSEcCtD
Conivaptan—Diarrhoea—Doxorubicin—liver cancer	0.00125	0.00249	CcSEcCtD
Conivaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.00125	0.00268	CbGpPWpGaD
Conivaptan—Headache—Epirubicin—liver cancer	0.00124	0.00246	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—F2—liver cancer	0.00124	0.00265	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—F2—liver cancer	0.00123	0.00263	CbGpPWpGaD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.00121	0.00259	CbGpPWpGaD
Conivaptan—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.00119	0.00255	CbGpPWpGaD
Conivaptan—Nausea—Epirubicin—liver cancer	0.00118	0.00233	CcSEcCtD
Conivaptan—Vomiting—Doxorubicin—liver cancer	0.00116	0.00231	CcSEcCtD
Conivaptan—Headache—Doxorubicin—liver cancer	0.00115	0.00228	CcSEcCtD
Conivaptan—AVPR1A—G alpha (q) signalling events—PIK3CA—liver cancer	0.0011	0.00235	CbGpPWpGaD
Conivaptan—Nausea—Doxorubicin—liver cancer	0.00109	0.00216	CcSEcCtD
Conivaptan—CYP3A4—Tryptophan metabolism—CYP1A1—liver cancer	0.00107	0.0023	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—liver cancer	0.00107	0.00229	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—PPARA—liver cancer	0.00106	0.00228	CbGpPWpGaD
Conivaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.00103	0.00221	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—FST—liver cancer	0.00103	0.0022	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—FST—liver cancer	0.00102	0.00218	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—PRKCE—liver cancer	0.00101	0.00216	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—PRKCE—liver cancer	0.001	0.00214	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—liver cancer	0.000982	0.0021	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TRIO—liver cancer	0.00098	0.0021	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.00098	0.0021	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TRIO—liver cancer	0.000973	0.00208	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—NR1H4—liver cancer	0.000955	0.00205	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CCR4—liver cancer	0.00094	0.00201	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTA3—liver cancer	0.000939	0.00201	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCR4—liver cancer	0.000933	0.002	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—GSTA3—liver cancer	0.000926	0.00198	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PRKCE—liver cancer	0.000916	0.00196	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PRKCE—liver cancer	0.000909	0.00195	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	0.000909	0.00195	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—CSF2—liver cancer	0.000892	0.00191	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—CSF2—liver cancer	0.000886	0.0019	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	0.00087	0.00186	CbGpPWpGaD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000868	0.00186	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTA4—liver cancer	0.000859	0.00184	CbGpPWpGaD
Conivaptan—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000857	0.00183	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—GSTA4—liver cancer	0.000847	0.00181	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTA2—liver cancer	0.000837	0.00179	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—CSF2—liver cancer	0.00081	0.00173	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTA1—liver cancer	0.000808	0.00173	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CSF2—liver cancer	0.000804	0.00172	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—NAT2—liver cancer	0.000798	0.00171	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—ALB—liver cancer	0.000791	0.00169	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—NAT2—liver cancer	0.000788	0.00169	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—ADAM17—liver cancer	0.000743	0.00159	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ADAM17—liver cancer	0.000737	0.00158	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—RAF1—liver cancer	0.000715	0.00153	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000704	0.00151	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—F2—liver cancer	0.0007	0.0015	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PSMA4—liver cancer	0.000698	0.0015	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PSMD10—liver cancer	0.000698	0.0015	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—F2—liver cancer	0.000695	0.00149	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PSMA4—liver cancer	0.000693	0.00148	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PSMD10—liver cancer	0.000693	0.00148	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—PIK3CG—liver cancer	0.00067	0.00143	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—GPX3—liver cancer	0.00067	0.00143	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—PIK3CG—liver cancer	0.000665	0.00142	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—HPGDS—liver cancer	0.000638	0.00137	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—F2—liver cancer	0.000636	0.00136	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—F2—liver cancer	0.000631	0.00135	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PIK3CG—liver cancer	0.000608	0.0013	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PIK3CG—liver cancer	0.000604	0.00129	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—PIK3CD—liver cancer	0.000589	0.00126	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—PIK3CD—liver cancer	0.000585	0.00125	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PRKCE—liver cancer	0.000541	0.00116	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PRKCE—liver cancer	0.000537	0.00115	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PIK3CD—liver cancer	0.000535	0.00115	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PIK3CD—liver cancer	0.000531	0.00114	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—CYP2E1—liver cancer	0.00052	0.00111	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—PIK3CB—liver cancer	0.000513	0.0011	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	0.000513	0.0011	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IGF2—liver cancer	0.000512	0.0011	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—PIK3CB—liver cancer	0.00051	0.00109	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IGF2—liver cancer	0.000509	0.00109	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CSF2—liver cancer	0.000479	0.00102	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GGT1—liver cancer	0.000478	0.00102	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—RAF1—liver cancer	0.000477	0.00102	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CSF2—liver cancer	0.000475	0.00102	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—RAF1—liver cancer	0.000474	0.00102	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—H2AFX—liver cancer	0.000472	0.00101	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—IL2—liver cancer	0.000471	0.00101	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—H2AFX—liver cancer	0.000468	0.001	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—IL2—liver cancer	0.000468	0.001	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PIK3CB—liver cancer	0.000466	0.000998	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PIK3CB—liver cancer	0.000463	0.000991	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTP1—liver cancer	0.000429	0.000919	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—IL2—liver cancer	0.000428	0.000917	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TERT—liver cancer	0.000427	0.000913	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—IL2—liver cancer	0.000425	0.00091	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TERT—liver cancer	0.000423	0.000907	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	0.000423	0.000906	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTM1—liver cancer	0.000394	0.000844	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—KDR—liver cancer	0.00039	0.000835	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	0.000389	0.000833	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MAPK14—liver cancer	0.000388	0.00083	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—KDR—liver cancer	0.000387	0.000829	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MAPK14—liver cancer	0.000385	0.000824	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—ESR1—liver cancer	0.00038	0.000814	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ESR1—liver cancer	0.000377	0.000808	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—F2—liver cancer	0.000376	0.000804	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—CYP1A1—liver cancer	0.000374	0.000801	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—F2—liver cancer	0.000373	0.000798	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	0.000369	0.00079	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PIK3CG—liver cancer	0.000359	0.00077	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—APC—liver cancer	0.000359	0.00077	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—APC—liver cancer	0.000357	0.000764	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PIK3CG—liver cancer	0.000357	0.000764	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—BRAF—liver cancer	0.000338	0.000723	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—BRAF—liver cancer	0.000335	0.000718	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PIK3CD—liver cancer	0.000316	0.000676	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PIK3CD—liver cancer	0.000314	0.000672	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—PIK3CA—liver cancer	0.000313	0.00067	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—SERPINE1—liver cancer	0.000312	0.000669	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—PIK3CA—liver cancer	0.000311	0.000665	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—SERPINE1—liver cancer	0.00031	0.000664	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—KRAS—liver cancer	0.000309	0.000662	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—KRAS—liver cancer	0.000307	0.000658	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PIK3CA—liver cancer	0.000284	0.000608	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PIK3CA—liver cancer	0.000282	0.000604	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—RAF1—liver cancer	0.000282	0.000604	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—RAF1—liver cancer	0.00028	0.0006	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—UGDH—liver cancer	0.00028	0.000599	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MTOR—liver cancer	0.000275	0.00059	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PIK3CB—liver cancer	0.000275	0.00059	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PIK3CB—liver cancer	0.000273	0.000585	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MTOR—liver cancer	0.000273	0.000585	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—HRAS—liver cancer	0.000263	0.000563	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—EPT1—liver cancer	0.000263	0.000563	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—HRAS—liver cancer	0.000261	0.000559	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CDKN1B—liver cancer	0.000258	0.000553	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CDKN1B—liver cancer	0.000257	0.000549	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—AKT1—liver cancer	0.000256	0.000547	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—AKT1—liver cancer	0.000254	0.000543	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CASP3—liver cancer	0.000253	0.000542	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IL2—liver cancer	0.000253	0.000542	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—IL6—liver cancer	0.000252	0.000539	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CASP3—liver cancer	0.000251	0.000538	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IL2—liver cancer	0.000251	0.000538	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—IL6—liver cancer	0.00025	0.000535	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—TAT—liver cancer	0.000249	0.000534	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CCND1—liver cancer	0.000247	0.000528	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—JUN—liver cancer	0.000246	0.000527	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCND1—liver cancer	0.000245	0.000524	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—JUN—liver cancer	0.000244	0.000523	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CTNNB1—liver cancer	0.000244	0.000523	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CTNNB1—liver cancer	0.000242	0.000519	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MMP9—liver cancer	0.000239	0.000513	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CDKN1A—liver cancer	0.000238	0.000511	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MMP9—liver cancer	0.000238	0.000509	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CDKN1A—liver cancer	0.000237	0.000507	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MAPK8—liver cancer	0.000233	0.000498	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—AKT1—liver cancer	0.000232	0.000497	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MAPK8—liver cancer	0.000231	0.000495	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—AKT1—liver cancer	0.00023	0.000494	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—VEGFA—liver cancer	0.000215	0.00046	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—VEGFA—liver cancer	0.000213	0.000457	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—STAT3—liver cancer	0.000213	0.000456	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—STAT3—liver cancer	0.000211	0.000452	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MYC—liver cancer	0.000198	0.000423	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TGFB1—liver cancer	0.000197	0.000422	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MYC—liver cancer	0.000196	0.00042	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TGFB1—liver cancer	0.000196	0.000419	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—KRAS—liver cancer	0.000183	0.000391	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—KRAS—liver cancer	0.000181	0.000388	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CPT1B—liver cancer	0.000169	0.000363	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GLUL—liver cancer	0.000169	0.000363	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PIK3CA—liver cancer	0.000168	0.000359	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PIK3CA—liver cancer	0.000167	0.000357	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—NR1H4—liver cancer	0.000163	0.00035	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TP53—liver cancer	0.000162	0.000348	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TP53—liver cancer	0.000161	0.000345	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTA3—liver cancer	0.000161	0.000344	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—HRAS—liver cancer	0.000155	0.000333	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—HRAS—liver cancer	0.000154	0.00033	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IL6—liver cancer	0.000149	0.000318	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IL6—liver cancer	0.000148	0.000316	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTA4—liver cancer	0.000147	0.000315	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTA2—liver cancer	0.000143	0.000307	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTA1—liver cancer	0.000138	0.000296	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—AKT1—liver cancer	0.000137	0.000294	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—NAT2—liver cancer	0.000137	0.000292	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—AKT1—liver cancer	0.000136	0.000292	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ALDOB—liver cancer	0.000131	0.00028	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CRABP1—liver cancer	0.000125	0.000267	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—HPGDS—liver cancer	0.000109	0.000234	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PSMA4—liver cancer	9.73e-05	0.000208	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PSMD10—liver cancer	9.73e-05	0.000208	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GOT2—liver cancer	9.47e-05	0.000203	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP2E1—liver cancer	8.9e-05	0.000191	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYCS—liver cancer	8.33e-05	0.000178	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GGT1—liver cancer	8.17e-05	0.000175	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GOT1—liver cancer	8.17e-05	0.000175	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTP1—liver cancer	7.34e-05	0.000157	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—HMOX1—liver cancer	7.24e-05	0.000155	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTM1—liver cancer	6.74e-05	0.000144	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP1A1—liver cancer	6.39e-05	0.000137	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—MTHFR—liver cancer	5.96e-05	0.000128	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PPARA—liver cancer	5.85e-05	0.000125	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PIK3CG—liver cancer	5.01e-05	0.000107	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PPARG—liver cancer	4.83e-05	0.000103	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PIK3CD—liver cancer	4.4e-05	9.43e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ALB—liver cancer	4.35e-05	9.31e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PIK3CB—liver cancer	3.84e-05	8.22e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PIK3CA—liver cancer	2.34e-05	5.01e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—AKT1—liver cancer	1.91e-05	4.09e-05	CbGpPWpGaD
